INDP

Indaptus Therapeutics, Inc. (INDP) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

INDP does not appear to have a durable brand, patent, or regulatory franchise that lets it charge peers a persistent premium, so pricing power versus competitors looks limited.

The provided TTM ROIC is deeply negative at -1.30%, which indicates the company is not converting any protected intangible position into economic returns better than peers.

No evidence was provided of proprietary IP, exclusive licenses, or regulated-market protection, so any intangible advantage appears weak and easily replicable relative to peers.

With no 5-year profitability or margin history supplied, there is no sign of a compounding intangible moat that would improve retention or pricing over a 5–10 year horizon.

Switching Costs

Score:

The available data do not show customer lock-in, contractual stickiness, or workflow integration that would make INDP materially harder to replace than peers.

Negative ROIC suggests customers are not paying for a differentiated embedded solution that preserves margins through retention.

No evidence was provided of high reimplementation costs, data migration friction, or compliance dependency, so switching costs appear low.

Compared with peers that benefit from recurring software, network, or regulated-service relationships, INDP’s retention advantage looks limited.

Network Effects

Score:

The metrics provided do not indicate a user, data, or transaction network that becomes more valuable as adoption rises, so network effects appear absent.

Negative returns on capital imply the business is not monetizing any ecosystem flywheel better than peers.

No evidence was provided of two-sided participation, platform dependency, or scale-driven engagement loops that would reinforce pricing power.

Relative to peer platforms with clear cross-side network benefits, INDP does not show a structural advantage that compounds over time.

Cost Advantage

Score:

The company’s negative ROIC suggests it is not operating with a cost structure that consistently beats peers on unit economics.

No evidence was provided of proprietary manufacturing scale, advantaged sourcing, or process superiority that would lower costs enough to sustain margin leadership.

Zero cash conversion cycle and zero asset turnover in the supplied data do not demonstrate a visible operating efficiency edge versus peers.

Without proof of lower delivered cost or superior capital productivity, any cost advantage appears weak and not durable.

Efficient Scale

Score:

The supplied information does not show that INDP serves a niche market with limited room for profitable entry, so efficient-scale protection is not evident.

Negative ROIC indicates the company is not earning excess returns from a protected market structure that would deter peers.

No evidence was provided of regulatory barriers, capacity constraints, or natural-monopoly economics that would support durable scale-based pricing power.

Compared with peers in industries where one or two players can efficiently dominate a niche, INDP does not show signs of structural scale insulation.

Overall Score

Score:

INDP shows no clear evidence of durable moat drivers in the supplied data, and the deeply negative TTM ROIC points to weak pricing power and limited capital efficiency versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Indaptus Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →